- EMA says no causal link yet of blood clots to either vaccine
- Four cases of blood clots in recipients of J&J shots
- J&J says working with regulators to assess data on its vaccine
- Probe of AstraZeneca vaccine and blood clots already ongoing
April 9 (Reuters) - Europe's drug regulator said on Friday it had started reviewing reports of a bleeding condition in people who had received AstraZeneca's (AZN.L) COVID-19 vaccine and was also looking into Johnson & Johnson's (JNJ.N) shot over blood clots.
Four serious cases of rare blood clots with low platelets, one of which was fatal, have been reported after inoculation with J&J's vaccine from its Janssen unit, the European Medicines Agency said, adding five cases of capillary leak syndrome in people who received AstraZeneca's vaccine were reported.
Our Standards: The Thomson Reuters Trust Principles.